Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.57 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | F2RL1 | P55085 | 4/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823958 | 1.00 | CTSL (0.57) | CTSLCTSSCTSKALDH1A1CTSB | |
| SCHEMBL12742961 | 0.85 | CTSS (0.55) | CTSLCTSSCTSKALDH1A1L3MBTL1 | |
| SCHEMBL5528235 | 0.83 | CTSL (0.71) | CTSLCTSSCTSKALDH1A1CTSB | |
| SCHEMBL12742962 | 0.83 | REN (0.54) | CTSLCTSSCTSKALDH1A1MMP2 | |
| SCHEMBL265813 | 0.82 | CTSL (0.67) | CTSLCTSSCTSKALDH1A1 | |
| SCHEMBL313931 | 0.81 | CTSS (0.48) | CTSLCTSSCTSKALDH1A1L3MBTL1 | |
| SCHEMBL272047 | 0.81 | CTSS (0.48) | CTSLCTSSCTSKALDH1A1L3MBTL1 | |
| SCHEMBL319351 | 0.81 | CTSS (0.53) | CTSLCTSSCTSKALDH1A1L3MBTL1 | |
| SCHEMBL272048 | 0.81 | CTSS (0.53) | CTSLCTSSCTSKALDH1A1L3MBTL1 | |
| SCHEMBL8334687 | 0.78 | CTSS (0.56) | CTSLCTSSCTSKALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133864-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133864-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-7910556-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090131330-A1 | PAR-2 AGONIST | KOWA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215703-A1 | PAR-2 Agonist | FPR2, F2RL1, FPR3 | CTSL 1479/4885CTSS 1558/4885CTSK 2813/4885 |
| US-20090131330-A1 | PAR-2 AGONIST | F2RL1, CNR2, FFAR2 | CTSL 2762/4885CTSS 3122/4885CTSK 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.